{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:27:59Z","timestamp":1793773679050,"version":"4.6.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The yeast\n                    <jats:italic>Saccharomyces boulardii<\/jats:italic>\n                    CNCM I-745 is a unique, non-bacterial microorganism classified as a probiotic agent. In this review article, at first, we briefly summarized the mechanisms responsible for its probiotic properties, e.g. adhesion to and elimination of enteropathogenic microorganisms and their toxins; extracellular cleavage of pathogens\u2019 virulent factors; trophic and anti-inflammatory effects on the intestinal mucosa. The efficacy of\n                    <jats:italic>S. boulardii<\/jats:italic>\n                    administration was tested in variety of human diseases. We discussed the results of\n                    <jats:italic>S. boulardii<\/jats:italic>\n                    CNCM I-745 use in the treatment or prevention of\n                    <jats:italic>Helicobacter pylori<\/jats:italic>\n                    infections, diarrhoea (\n                    <jats:italic>Clostridium difficile<\/jats:italic>\n                    infections, antibiotic-associated diarrhoea, and traveller\u2019s diarrhoea), inflammatory bowel diseases, irritable bowel syndrome, candidiasis, dyslipidemia, and small intestine bacterial overgrowth in patients with multiple sclerosis. In case of limited number of studies regarding this strain, we also presented studies demonstrating properties and efficacy of other strains of\n                    <jats:italic>S. boulardii.<\/jats:italic>\n                    Administration of\n                    <jats:italic>S. boulardii<\/jats:italic>\n                    CNCMI I-745 during antibiotic therapy has certain advantage over bacterial probiotics, because\u2014due to its fungal natural properties\u2014it is intrinsically resistant to the antibiotics and cannot promote the spread of antimicrobial resistance. Even though cases of fungemia following\n                    <jats:italic>S. boulardii<\/jats:italic>\n                    CNCM I-745 administration were reported, it should be treated as a widely available and safe probiotic strain.\n                  <\/jats:p>","DOI":"10.1007\/s00284-020-02053-9","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T14:02:48Z","timestamp":1590760968000},"page":"1987-1996","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0283-1436","authenticated-orcid":false,"given":"Karolina","family":"Ka\u017amierczak-Siedlecka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Ruszkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Fic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Folwarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Makarewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"2053_CR1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cca.2015.01.003","volume":"451","author":"V D'Argenio","year":"2015","unstructured":"D'Argenio V, Salvatore F (2015) The role of gut microbiota in the healthy adult status. Clin Chim Acta 451:97\u2013102","journal-title":"Clin Chim Acta"},{"key":"2053_CR2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.gendis.2014.08.001","volume":"1","author":"J Sun","year":"2014","unstructured":"Sun J, Chang EB (2014) Exploring gut microbes in human health and disease: pushing the envelope. Genes Dis 1:132\u2013139","journal-title":"Genes Dis"},{"key":"2053_CR3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrgastro.2014.188","volume":"2","author":"PK Mukherjee","year":"2015","unstructured":"Mukherjee PK, Sendid B, Hoarau G et al (2015) Mycobiota in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 2:77\u201387","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2053_CR4","first-page":"4742","volume":"22","author":"S Bibbo","year":"2016","unstructured":"Bibbo S, Ianiro G, Giorgio V et al (2016) The role of diet on gut microbiota composition. Eur Rev Med Pharmacol Sci 22:4742\u20134797","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2053_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201600240","author":"B S\u00e1nchez","year":"2017","unstructured":"S\u00e1nchez B, Delgado S, Blanco-M\u00edguez A et al (2017) Probiotics, gut microbiota, and their influence on host health and disease. Mol Nutr Food Res. https:\/\/doi.org\/10.1002\/mnfr.201600240","journal-title":"Mol Nutr Food Res"},{"key":"2053_CR6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","volume":"8","author":"GR Gibson","year":"2017","unstructured":"Gibson GR, Hutkins R, Sanders ME et al (2017) Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 8:491\u2013502","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2053_CR7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13054-018-2167-x","volume":"1","author":"K Shimizu","year":"2018","unstructured":"Shimizu K, Yamada T, Ogura H et al (2018) Synbiotics modulate gut microbiota and reduce enteritis and ventilator-associated pneumonia in patients with sepsis: a randomized controlled trial. Crit Care 1:239","journal-title":"Crit Care"},{"key":"2053_CR8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fphar.2017.00603","volume":"8","author":"GL Banna","year":"2017","unstructured":"Banna GL, Torino F, Marletta F et al (2017) Lactobacillus rhamnosus GG: an overview to explore the rationale of its use in cancer. Front Pharmacol 8:603","journal-title":"Front Pharmacol"},{"key":"2053_CR9","first-page":"1","volume":"1","author":"K Ka\u017amierczak-Siedlecka","year":"2019","unstructured":"Ka\u017amierczak-Siedlecka K, Piekarska A, Lubieniecka-Archutowska E et al (2019) Nutritional status in patients after hematopoietic cell transplantation. Acta Haeamtol Pol 1:1\u20139","journal-title":"Acta Haeamtol Pol"},{"key":"2053_CR10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.anaerobe.2019.06.002","volume":"59","author":"J Ruszkowski","year":"2019","unstructured":"Ruszkowski J, Witkowski JM (2019) Lactulose: patient- and dose-dependent prebiotic properties in humans. Anaerobe 59:100\u2013106","journal-title":"Anaerobe"},{"key":"2053_CR11","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.3748\/wjg.v25.i18.2188","volume":"18","author":"D Czerucka","year":"2019","unstructured":"Czerucka D, Rampal P (2019) Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infection. World J Gastroenterol 18:2188\u20132203","journal-title":"World J Gastroenterol"},{"key":"2053_CR12","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1128\/AEM.02201-06","volume":"8","author":"L Edwards-Ingram","year":"2007","unstructured":"Edwards-Ingram L, Gitsham P, Burton N et al (2007) Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl Environ Microbiol 8:2458\u20132467","journal-title":"Appl Environ Microbiol"},{"key":"2053_CR13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.medmal.2017.07.001","volume":"7","author":"C Neut","year":"2017","unstructured":"Neut C, Mahieux S, Dubreuil LJ (2017) Antibiotic susceptibility of probiotic strains: is it reasonable to combine probiotics with antibiotics? Med Male Infect 7:477\u2013483","journal-title":"Med Male Infect"},{"key":"2053_CR14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2147\/CEG.S85574","volume":"8","author":"MI Mor\u00e9","year":"2015","unstructured":"Mor\u00e9 MI, Swidsinski A (2015) Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis\u2014a review. Clin Exp Gastroenterol 8:237\u2013255","journal-title":"Clin Exp Gastroenterol"},{"key":"2053_CR15","doi-asserted-by":"crossref","first-page":"117955221775267","DOI":"10.1177\/1179552217752679","volume":"11","author":"MI Mor\u00e9","year":"2019","unstructured":"Mor\u00e9 MI, Vandenplas Y (2019) Saccharomyces boulardii CNCM I-745 improves intestinal enzyme function: a trophic effects review. Clin Med Insights Gastroenterol 11:1179552217752679","journal-title":"Clin Med Insights Gastroenterol"},{"key":"2053_CR16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41598-017-00414-2","volume":"7","author":"I Khatri","year":"2017","unstructured":"Khatri I, Tomar R, Ganesan K et al (2017) Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii. Sci Rep 7:371","journal-title":"Sci Rep"},{"key":"2053_CR17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1128\/JCM.39.2.551-559.2001","volume":"2","author":"C Hennequin","year":"2001","unstructured":"Hennequin C, Thierry A, Richard GF et al (2001) Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J Clin Microbiol 2:551\u2013559","journal-title":"J Clin Microbiol"},{"key":"2053_CR18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijfoodmicro.2004.12.031","volume":"3","author":"B Posteraro","year":"2005","unstructured":"Posteraro B, Sanguinetti M, Romano L et al (2005) Molecular tools for differentiating probiotic and clinical strains of Saccharomyces cerevisiae. Int J Food Microbiol 3:295\u2013304","journal-title":"Int J Food Microbiol"},{"key":"2053_CR19","first-page":"e02858","volume":"10","author":"J Liu","year":"2018","unstructured":"Liu J, Zhang G, Kong I et al (2018) A mutation in PGM2 causing inefficient galactose metabolism by the probiotic yeast Saccharomyces boulardii. Appl Environ Microbiol 10:e02858\u2013e2917","journal-title":"Appl Environ Microbiol"},{"key":"2053_CR20","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1101\/gr.243147.118","volume":"9","author":"B Offei","year":"2019","unstructured":"Offei B, Vandecruys P, De Graeve S et al (2019) Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast Saccharomyces cerevisiae var. boulardii. Genome Res 9:1478\u20131494","journal-title":"Genome Res"},{"key":"2053_CR21","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1128\/AEM.71.10.6008-6013.2005","volume":"10","author":"D Fayol-Messaoudi","year":"2005","unstructured":"Fayol-Messaoudi D, Berger CN, Coconnier-Polter M et al (2005) pH-, lactic acid-, and non-lactic acid-dependent activities of probiotic Lactobacilli against Salmonella Enterica serovar typhimurium. Appl Environ Microbiol 10:6008\u20136013","journal-title":"Appl Environ Microbiol"},{"key":"2053_CR22","doi-asserted-by":"crossref","first-page":"e2586","DOI":"10.1126\/scitranslmed.aao2586","volume":"445","author":"N Mao","year":"2018","unstructured":"Mao N, Andres Cubillos-Ruiz A, Ewen Cameron E et al (2018) Probiotic strains detect and suppress cholera in mice. Sci Transl Med 445:e2586","journal-title":"Sci Transl Med"},{"key":"2053_CR23","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1186\/s13099-019-0287-8","volume":"11","author":"M Lepczy\u0144ska","year":"2019","unstructured":"Lepczy\u0144ska M, Dzika E (2019) The influence of probiotic bacteria and human gut microorganisms causing opportunistic infections on Blastocystis ST3. Gut Pathogens 11:e6","journal-title":"Gut Pathogens"},{"key":"2053_CR24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF01536771","volume":"2","author":"JP Buts","year":"1990","unstructured":"Buts JP, Bernasconi P, Vaerman JP et al (1990) Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces Boulardii. Dig Dis Sci 2:251\u2013256","journal-title":"Dig Dis Sci"},{"key":"2053_CR25","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1128\/IAI.69.4.2762-2765.2001","volume":"4","author":"A Qamar","year":"2001","unstructured":"Qamar A, Aboudola S, Warny M et al (2001) Saccharomyces Boulardii stimulates intestinal immunoglobulin A immune response to clostridium difficile toxin A in Mice. Infect Immun 4:2762\u20132765","journal-title":"Infect Immun"},{"key":"2053_CR26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/mi.2011.41","volume":"6","author":"NJ Mantis","year":"2011","unstructured":"Mantis NJ, Rol N, Corth\u00e9sy B (2011) Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol 6:603\u2013611","journal-title":"Mucosal Immunol"},{"key":"2053_CR27","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1128\/IAI.64.12.5225-5232.1996","volume":"12","author":"I Castagliuolo","year":"1996","unstructured":"Castagliuolo I, LaMont JT, Nikulasson ST et al (1996) Saccharomyces boulardii protease inhibits Clostridium difficile Toxin A effects in the rat ileum. Infect Immun 12:5225\u20135232","journal-title":"Infect Immun"},{"key":"2053_CR28","doi-asserted-by":"crossref","first-page":"24449","DOI":"10.1074\/jbc.M605200200","volume":"34","author":"X Chen","year":"2006","unstructured":"Chen X, Kokkotou EG, Mustafa N et al (2006) Saccharomyces Boulardii inhibits ERK1\/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 34:24449\u201324454","journal-title":"J Biol Chem"},{"key":"2053_CR29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0399-8320(10)70024-5","volume":"1","author":"A Collignon","year":"2010","unstructured":"Collignon A, Sandr\u00e9 C, Barc MC (2010) Saccharomyces boulardii modulates dendritic cell properties and intestinal microbiota disruption after antibiotic treatment. Gastroenterol Clin Biol 1:71\u201378","journal-title":"Gastroenterol Clin Biol"},{"key":"2053_CR30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.anaerobe.2008.04.003","volume":"14","author":"MC Barc","year":"2010","unstructured":"Barc MC, Charrin-Sarnel C, Rochet V et al (2010) Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii. Anaerobe 14:229\u2013233","journal-title":"Anaerobe"},{"key":"2053_CR31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.syapm.2015.11.002","volume":"1","author":"A Swidsinski","year":"2016","unstructured":"Swidsinski A, Loening-Baucke V, Schulz S et al (2016) Functional anatomy of the colonic bioreactor: impact of antibiotics and Saccharomyces Boulardii on bacterial composition in human fecal cylinders. Syst Appl Microbiol 1:67\u201375","journal-title":"Syst Appl Microbiol"},{"key":"2053_CR32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/19490976.2016.1267890","volume":"1","author":"TA Kabbani","year":"2017","unstructured":"Kabbani TA, Pallav K, Dowd SE et al (2017) Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of the healthy volunteers. Gut Microbes 1:17\u201332","journal-title":"Gut Microbes"},{"key":"2053_CR33","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fmicb.2019.00336","volume":"10","author":"CP Kelly","year":"2019","unstructured":"Kelly CP, Nguyen CC, Palmieri LJ et al (2019) Saccharomyces boulardii CNCM I-745 modulates the fecal bile acids metabolism during antimicrobial therapy in healthy volunteers. Front Microbiol 10:336","journal-title":"Front Microbiol"},{"key":"2053_CR34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/eos.12425","volume":"1","author":"H Valen","year":"2018","unstructured":"Valen H, Scheie AA (2018) Biofilms and their properties. Eur J Oral Sci 1:13\u201318","journal-title":"Eur J Oral Sci"},{"key":"2053_CR35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/CEG.S181590","volume":"12","author":"C Terciolo","year":"2019","unstructured":"Terciolo C, Dapoigny M, Andre F (2019) Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption. Clin Exp Gastroenterol 12:67\u201382","journal-title":"Clin Exp Gastroenterol"},{"key":"2053_CR36","first-page":"599","volume":"3","author":"KL Mumy","year":"2003","unstructured":"Mumy KL, Chen X, Kelly CP et al (2003) Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. Am J Physiol Gastrointest Liver Physiol 3:599\u2013609","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2053_CR37","doi-asserted-by":"crossref","first-page":"99830","DOI":"10.1371\/journal.pone.0099830","volume":"6","author":"V Buccigrossi","year":"2014","unstructured":"Buccigrossi V, Laudiero G, Russo C et al (2014) Chloride secretion induced by rotavirus is oxidative stress-dependent and inhibited by Saccharomyces boulardii in human enterocytes. PLoS ONE 6:99830","journal-title":"PLoS ONE"},{"key":"2053_CR38","first-page":"e3768","volume":"1","author":"K Namkin","year":"2016","unstructured":"Namkin K, Zardast M, Basirinejad F (2016) Saccharomyces boulardii in Helicobacter pylori eradication in children: a randomized trial from Iran. Iran J Pediatr 1:e3768","journal-title":"Iran J Pediatr"},{"key":"2053_CR39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5223\/pghn.2015.18.1.17","volume":"1","author":"Z Bin","year":"2015","unstructured":"Bin Z, Ya-Zheng X, Zhao-Hui D et al (2015) The efficiency of Saccharomyces boulardii CNCM I-745 in addition to standard Helicobacter pylori eradication treatment in children. Pediatr Gastroenterol Hepatol Nutr 1:17\u201322","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"2053_CR40","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00228-019-02625-0","volume":"5","author":"H Seddik","year":"2019","unstructured":"Seddik H, Boutallaka H, Elkoti I et al (2019) Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial. Eur J Clin Pharmacol 5:639\u2013645","journal-title":"Eur J Clin Pharmacol"},{"key":"2053_CR41","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/apt.13214","volume":"12","author":"H Szajewska","year":"2015","unstructured":"Szajewska H, Horvath A, Ko\u0142odziej M (2015) Systematic review and meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 12:1237\u20131245","journal-title":"Aliment Pharmacol Ther"},{"key":"2053_CR42","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/apm.12237","volume":"10","author":"S Sakarya","year":"2014","unstructured":"Sakarya S, Gunay N (2014) Saccharomyces boulardii expresses neuraminidase activity selective for \u03b12,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS 10:941\u2013950","journal-title":"APMIS"},{"key":"2053_CR43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3920\/BM2014.0086","volume":"4","author":"EC Dinleyici","year":"2015","unstructured":"Dinleyici EC, Kara A, Dalgic N et al (2015) Saccharomyces Boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea. Benef Microbes 4:415\u2013421","journal-title":"Benef Microbes"},{"key":"2053_CR44","first-page":"269","volume":"2","author":"SJ Vermeersch","year":"2018","unstructured":"Vermeersch SJ, Vandenplas Y, Tanghe A et al (2018) Economic evaluation of S. boulardii CNCM I-745 for prevention of antibiotic-associated diarrhoea in hospitalized patients. Acta Gastroenterol Belg 2:269\u2013276","journal-title":"Acta Gastroenterol Belg"},{"key":"2053_CR45","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/apt.13344","volume":"7","author":"H Szajewska","year":"2015","unstructured":"Szajewska H, Ko\u0142odziej M (2015) Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 7:793\u2013801","journal-title":"Aliment Pharmacol Ther"},{"key":"2053_CR46","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s10096-018-3267-x","volume":"8","author":"JW Carstensen","year":"2018","unstructured":"Carstensen JW, Chehri M, Schonning K et al (2018) Use of prophylatic Saccharomyces boulardii to prevent Clostridium difficile infection in hospitalized patients: a controlled prospective intervention study. Eur J Clin Microbiol Infect Dis 8:1431\u20131439","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2053_CR47","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1128\/JB.01765-07","volume":"7","author":"JA Sorg","year":"2008","unstructured":"Sorg JA, Sonenshein AL (2008) Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 7:2505\u20132512","journal-title":"J Bacteriol"},{"key":"2053_CR48","doi-asserted-by":"crossref","first-page":"00045","DOI":"10.1128\/mSphere.00045-15","volume":"1","author":"CM Theriot","year":"2016","unstructured":"Theriot CM, Bowman AA, Young VB (2016) Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for Clostridium difficile spore germination and outgrowth in the large intestine. mSphere 1:00045","journal-title":"mSphere"},{"key":"2053_CR49","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.anaerobe.2017.03.004","volume":"45","author":"R Thanissery","year":"2017","unstructured":"Thanissery R, Winston JA, Theriota CM (2017) Inhibition of spore germination, growth, and toxin activity of clinically relevant C. difficile strains by gut microbiota derived secondary bile acids. Anaerobe 45:86\u2013100","journal-title":"Anaerobe"},{"key":"2053_CR50","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fmicb.2019.00336","volume":"10","author":"CP Kelly","year":"2019","unstructured":"Kelly CP, Chong Nguyen C, Palmieri LJ et al (2019) Saccharomyces boulardii CNCM I-745 modulates the fecal bile acids metabolism during antimicrobial therapy in healthy volunteers. Front Microbiol 10:336","journal-title":"Front Microbiol"},{"key":"2053_CR51","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1152\/ajpgi.00150.2016","volume":"4","author":"HW Koon","year":"2016","unstructured":"Koon HW, Su B, Xu C et al (2016) Probiotic Saccharomyces boulardii CNCM I-745 prevents outbreak-associated Clostridium difficile associated cecal inflammation in hamsters. Am J Physiol Gastrointest Liver Physiol 4:610\u2013624","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2053_CR52","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1155\/2009\/915847","volume":"12","author":"JM Tung","year":"2009","unstructured":"Tung JM, Dolovich LR, Lee CH (2009) Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review. Can J Gastroenterol 12:817\u2013821","journal-title":"Can J Gastroenterol"},{"key":"2053_CR53","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/0016-5085(89)91613-2","volume":"96","author":"CM Surawicz","year":"1986","unstructured":"Surawicz CM, Elmer GW, Speelman P et al (1986) Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: A prospective study. Gastroenterology 96:981\u2013986","journal-title":"Gastroenterology"},{"key":"2053_CR54","first-page":"439","volume":"3","author":"LV McFarland","year":"1995","unstructured":"McFarland LV, Surawicz CM, Greenberg RN et al (1995) Prevention of beta-lactam-associated diarrhea by Saccharomyces Boulardii compared with placebo. Am J Gastroenterol 3:439\u2013448","journal-title":"Am J Gastroenterol"},{"key":"2053_CR55","first-page":"ofw011","volume":"1","author":"S Ehrhardt","year":"2006","unstructured":"Ehrhardt S, Guo N, Hinz R et al (2006) Saccharomyces boulardii to prevent antibiotic-associated diarrhea: a randomized, double-masked, Placebo-Controlled Trial. Open Forum Infect Dis. 1:ofw011","journal-title":"Open Forum Infect Dis."},{"key":"2053_CR56","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s10096-018-3267-x","volume":"37","author":"JW Carstensen","year":"2018","unstructured":"Carstensen JW, Chehri M, Sch\u00f8nning K et al (2018) Use of prophylactic Saccharomyces boulardii to prevent Clostridium Difficile infection in hospitalized patients: a controlled prospective intervention study. Eur J Clin Microbiol & Inf Dis 37:1431\u20131439","journal-title":"Eur J Clin Microbiol & Inf Dis"},{"key":"2053_CR57","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1001\/jama.1994.03510480037031","volume":"271","author":"LV McFarland","year":"2014","unstructured":"McFarland LV, Surawicz CM, Greenberg RN et al (2014) A randomized placebo-controlled trail of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271:1913\u20131918","journal-title":"JAMA"},{"key":"2053_CR58","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1086\/318130","volume":"31","author":"CM Surawicz","year":"2000","unstructured":"Surawicz CM, McFarland LV, Greenberg RN et al (2000) The search for a better treatment for recurrent Clostridium difficile disease: Use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31:1012\u20131017","journal-title":"Clin Infect Dis"},{"key":"2053_CR59","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11894-011-0208-6","volume":"5","author":"M Paredes-Paredes","year":"2011","unstructured":"Paredes-Paredes M, Flores-Figueroa J, Dupont HL (2011) Advances in the treatment of travellers' diarrhea. Curr Gastroenterol Rep 5:402\u2013407","journal-title":"Curr Gastroenterol Rep"},{"key":"2053_CR60","first-page":"317","volume":"2","author":"SL Giddings","year":"2016","unstructured":"Giddings SL, Stevens AM, Leung DT (2016) Travellers' diarrhea. Med Clin 2:317\u2013330","journal-title":"Med Clin"},{"key":"2053_CR61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tmaid.2018.09.007","volume":"27","author":"L McFarland","year":"2019","unstructured":"McFarland L, Goh S (2019) Are probiotics and prebiotics effective in the prevention of travellers' diarrhea: a systematic review and meta-analysis. Travel Med Infect Dis 27:11\u201319","journal-title":"Travel Med Infect Dis"},{"key":"2053_CR62","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/ecco-jcc\/jjx030","volume":"8","author":"C Terciolo","year":"2017","unstructured":"Terciolo C, Dobric A, Ouaissi M et al (2017) Saccharomyces boulardii CNCM I-745 restores intestinal barrier integrity by regulation of E-cadherin recycling. J Crohns Colitis 8:999\u20131010","journal-title":"J Crohns Colitis"},{"key":"2053_CR63","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1097\/CM9.0000000000000364","volume":"16","author":"JP Dong","year":"2019","unstructured":"Dong JP, Zheng Y, Wu T et al (2019) Protective effect of Saccharomyces boulardii on intestinal mucosal barrier of dextran sodium sulfate-induced colitis in mouse. Chin Med J 16:1951\u20131958","journal-title":"Chin Med J"},{"key":"2053_CR64","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/00042737-200110000-00004","volume":"13","author":"K Niedzielin","year":"2001","unstructured":"Niedzielin K, Kordecki H, Birkenfeld B (2001) A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299v in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 13:1143\u20131147","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2053_CR65","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/MCG.0b013e318204593e","volume":"8","author":"CH Choi","year":"2011","unstructured":"Choi CH, Jo SY, Park HJ et al (2011) A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 8:679\u2013683","journal-title":"J Clin Gastroenterol"},{"key":"2053_CR66","doi-asserted-by":"crossref","first-page":"e0181863","DOI":"10.1371\/journal.pone.0181863","volume":"7","author":"P Brun","year":"2017","unstructured":"Brun P, Scarpa M, Marchiori C et al (2017) Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS. PLoS ONE 7:e0181863","journal-title":"PLoS ONE"},{"key":"2053_CR67","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/MEG.0000000000000094","volume":"6","author":"Z Abbas","year":"2014","unstructured":"Abbas Z, Yakoob J, Jafri W et al (2014) Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur J Gastroenterol Hepatol 6:630\u2013639","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2053_CR68","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fmed.2018.00124","volume":"5","author":"LV McFarland","year":"2018","unstructured":"McFarland LV, Evans CT, Goldstein EJC (2018) Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Front Med 5:124","journal-title":"Front Med"},{"key":"2053_CR69","doi-asserted-by":"crossref","first-page":"e12050","DOI":"10.1371\/journal.pone.0012050","volume":"8","author":"A Murzyn","year":"2010","unstructured":"Murzyn A, Krasowska A, Stefanowicz P et al (2010) Capric acid secreted by S. boulardii inhibits C. albicans filamentous growth Adhesion and Biofilm Formation. PLoS ONE 8:e12050","journal-title":"PLoS ONE"},{"key":"2053_CR70","first-page":"e59891","volume":"3","author":"R Salehi","year":"2018","unstructured":"Salehi R, Bayat M, Owlia P et al (2018) Effect of Saccharomyces boulardii extract on SAP2 gene expression and antifungal susceptibility of Candida albicans. Jundishapur J Microbiol 3:e59891","journal-title":"Jundishapur J Microbiol"},{"key":"2053_CR71","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3920\/BM2018.0134","volume":"5","author":"F Briand","year":"2019","unstructured":"Briand F, Sulpice T, Giammarinaro P et al (2019) Saccharomyces boulardii CNCM I-745 changes lipidemic profile and gut microbiota in a hamster hypercholesterolemic model. Benef Microbes 5:555\u2013567","journal-title":"Benef Microbes"},{"key":"2053_CR72","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s13063-019-3454-9","volume":"1","author":"D Aghammohammadi","year":"2019","unstructured":"Aghammohammadi D, Ayromlou H, Dolatkhan N et al (2019) The effects of probiotic Saccharomyces boulardii on the mental health, quality of life, fatigue, pain, and indices of inflammation and oxidative stress in patients with multiple sclerosis: study protocol for a double-blind randomized controlled clinical trial. Trials 1:379","journal-title":"Trials"},{"key":"2053_CR73","doi-asserted-by":"crossref","first-page":"e13494","DOI":"10.1111\/nmo.13494","volume":"11","author":"M Di Stefano","year":"2018","unstructured":"Di Stefano M, Quigley EMM (2018) The diagnosis of small intestinal bacterial overgrowth: two steps forward, one step backwards? Neurogastroenterol Motil 11:e13494","journal-title":"Neurogastroenterol Motil"},{"key":"2053_CR74","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2016.11.004","volume":"301","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Liu G, Duan Y et al (2016) Prevalence of small intestinal bacterial overgrowth in multiple sclerosis: a case-control study from China. J Neuroimmunol 301:83\u201387","journal-title":"J Neuroimmunol"},{"key":"2053_CR75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s100960050003","volume":"19","author":"C Hennequin","year":"2019","unstructured":"Hennequin C, Kauffmann-Lacroix C, Jobert A et al (2019) Possible Role of Catheters in Saccharomyces Boulardii Fungemia. Eur J Clin Microbiol Infect Dis 19:16\u201320","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2053_CR76","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1081-1206(10)60154-8","volume":"1","author":"J Hwang","year":"2009","unstructured":"Hwang J, Kang K, Kang Y et al (2009) Probiotic gastrointestinal allergic reaction caused by Saccharomyces Boulardii. Ann Allergy Asthma Immunol 1:87\u201388","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2053_CR77","first-page":"e176","volume":"1","author":"S Feizizadeh","year":"2014","unstructured":"Feizizadeh S, Salehi-Abargouei A, Akbari V (2014) Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Offic J American Acad Pediatrics 1:e176\u2013e191","journal-title":"Offic J American Acad Pediatrics"},{"key":"2053_CR78","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s12602-017-9332-4","volume":"2","author":"B Sulik-Tyszka","year":"2018","unstructured":"Sulik-Tyszka B, Snarski E, Nied\u017awiedzka M et al (2018) Experience with Saccharomyces boulardii probiotic in oncohaematological patients. Probiotics Antimicrob Proteins 2:350\u2013355","journal-title":"Probiotics Antimicrob Proteins"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-020-02053-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-020-02053-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-020-02053-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T19:44:18Z","timestamp":1622231058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-020-02053-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["2053"],"URL":"https:\/\/doi.org\/10.1007\/s00284-020-02053-9","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"21 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Accepted by all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}